Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34895487

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jan
First author
Jacobson CA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):6-8. doi: 10.1016/S1470-2045(21)00648-3.
    note
    Source null
    related pmid
    34895488
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Mar;19(3):150. doi: 10.1038/s41571-021-00596-9.
    note
    Source null
    related pmid
    34937949
    relationship
    Comment in

Authors and identifiers

  1. name
    Jacobson CA
    type
    Author
  2. name
    Chavez JC
    type
    Author
  3. name
    Sehgal AR
    type
    Author
  4. name
    William BM
    type
    Author
  5. name
    Munoz J
    type
    Author
  6. name
    Salles G
    type
    Author
  7. name
    Munshi PN
    type
    Author
  8. name
    Casulo C
    type
    Author
  9. name
    Maloney DG
    type
    Author
  10. name
    de Vos S
    type
    Author
  11. name
    Reshef R
    type
    Author
  12. name
    Leslie LA
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Jacobson CA
    type
    Author
  2. name
    Chavez JC
    type
    Author
  3. name
    Sehgal AR
    type
    Author
  4. name
    William BM
    type
    Author
  5. name
    Munoz J
    type
    Author
  6. name
    Salles G
    type
    Author
  7. name
    Munshi PN
    type
    Author
  8. name
    Casulo C
    type
    Author
  9. name
    Maloney DG
    type
    Author
  10. name
    de Vos S
    type
    Author
  11. name
    Reshef R
    type
    Author
  12. name
    Leslie LA
    type
    Author
bibliography ids
  1. nci-bib-0909c99760ec331951815ceb
book metadata
content sha256
7d69973487cd2878120c7a39ece6f90740d576a974ab729c4f3dd7aa722caebf
document type
citation
dois
  1. 10.1016/S1470-2045(21)00591-X
electronic publication date
display
2021 Dec 8
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34895487
immutable id
pubmed:34895487@7d69973487cd2878120c7a39ece6f90740d576a974ab729c4f3dd7aa722caebf
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
91-103
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):6-8. doi: 10.1016/S1470-2045(21)00648-3.
    note
    Source null
    related pmid
    34895488
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Mar;19(3):150. doi: 10.1038/s41571-021-00596-9.
    note
    Source null
    related pmid
    34937949
    relationship
    Comment in
outcomes validated
false
pmid
34895487
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
1510d7a0f4d314105ba5f1fe2a427002fb57ed53660f8b8f4afad961ff821634
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34895487/
title
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice